Current Search Criteria: Intervention: Bortezomib, cyclophosphamide, thalidomide, dexamethasone
Found 27 matching trials
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma PHASE2 The purpose of this Phase 2 randomized study is to evaluate the efficacy an...
Show More Location
Wilhelminenspital-1
Learn More & Join Trial
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients PHASE3 The purpose of this study is to compare a standard chemotherapy regimen of ...
Show More Location
112 sites UK wide
Treatments Being Tested
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance High dose melphalan therapy and autologous stem cell transplant (intensive pathway only) Learn More & Join Trial
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy PHASE3 With this study - Total Therapy IIIB - researchers are extending the findin...
Show More Status
Active Not Recruiting
Location
University of Arkansas for Medical Sciences/Myeloma Institute
Learn More & Join Trial
GEM05 for Patients With Multiple Myeloma Under 65 Years PHASE3 The primary objective is to compare safety and efficacy of three induction ...
Show More Location
Hospital General de Alicante
Learn More & Join Trial
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia PHASE2 RATIONALE: Sometimes the cancer may not need treatment until it progresses....
Show More Location
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Learn More & Join Trial
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation PHASE3 This study compared two main different induction protocols used to treat my...
Show More Location
Multiple Locations
Learn More & Join Trial
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) PHASE2 In this study, the investigators will analyze the long-term outcomes of rem...
Show More Location
Chonnam National University Hwasun Hospital
Learn More & Join Trial
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy PHASE2 There have been four previous Total Therapy (TT1 through IIIB) studies for ...
Show More Status
Active Not Recruiting
Location
University of Arkansas for Medical Sciences
Learn More & Join Trial
Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. PHASE2 This study evaluates a new treatment combination of ixazomib with cyclophos...
Show More Location
Queen Elizabeth Medical Centre
Learn More & Join Trial
Modified Bortezomib-based Combination Therapy for Multiple Myeloma PHASE4 To investigate the efficacy of a modified bortezomib based combination ther...
Show More Location
Shanghai General Hospital
Learn More & Join Trial